CYTH vs. CLYM, ENTA, SKYE, ATOS, XBIT, ALGS, EDIT, ZURA, ARTV, and ANIX
Should you be buying Cyclo Therapeutics stock or one of its competitors? The main competitors of Cyclo Therapeutics include Climb Bio (CLYM), Enanta Pharmaceuticals (ENTA), Skye Bioscience (SKYE), Atossa Therapeutics (ATOS), XBiotech (XBIT), Aligos Therapeutics (ALGS), Editas Medicine (EDIT), Zura Bio (ZURA), Artiva Biotherapeutics (ARTV), and Anixa Biosciences (ANIX). These companies are all part of the "pharmaceutical products" industry.
Cyclo Therapeutics vs.
Cyclo Therapeutics (NASDAQ:CYTH) and Climb Bio (NASDAQ:CLYM) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their risk, media sentiment, community ranking, profitability, institutional ownership, dividends, earnings, analyst recommendations and valuation.
Cyclo Therapeutics has higher revenue and earnings than Climb Bio. Cyclo Therapeutics is trading at a lower price-to-earnings ratio than Climb Bio, indicating that it is currently the more affordable of the two stocks.
Cyclo Therapeutics received 8 more outperform votes than Climb Bio when rated by MarketBeat users. However, 100.00% of users gave Climb Bio an outperform vote while only 71.43% of users gave Cyclo Therapeutics an outperform vote.
In the previous week, Climb Bio had 4 more articles in the media than Cyclo Therapeutics. MarketBeat recorded 4 mentions for Climb Bio and 0 mentions for Cyclo Therapeutics. Cyclo Therapeutics' average media sentiment score of 0.00 beat Climb Bio's score of -0.07 indicating that Cyclo Therapeutics is being referred to more favorably in the media.
Climb Bio has a net margin of 0.00% compared to Cyclo Therapeutics' net margin of -2,847.19%. Cyclo Therapeutics' return on equity of 0.00% beat Climb Bio's return on equity.
Cyclo Therapeutics presently has a consensus price target of $0.95, indicating a potential downside of 2.61%. Climb Bio has a consensus price target of $10.00, indicating a potential upside of 557.89%. Given Climb Bio's stronger consensus rating and higher possible upside, analysts plainly believe Climb Bio is more favorable than Cyclo Therapeutics.
68.6% of Cyclo Therapeutics shares are held by institutional investors. Comparatively, 69.8% of Climb Bio shares are held by institutional investors. 29.8% of Cyclo Therapeutics shares are held by company insiders. Comparatively, 3.2% of Climb Bio shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
Cyclo Therapeutics has a beta of -0.49, suggesting that its share price is 149% less volatile than the S&P 500. Comparatively, Climb Bio has a beta of -0.24, suggesting that its share price is 124% less volatile than the S&P 500.
Summary
Climb Bio beats Cyclo Therapeutics on 10 of the 17 factors compared between the two stocks.
Get Cyclo Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for CYTH and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Cyclo Therapeutics Competitors List
Related Companies and Tools
This page (NASDAQ:CYTH) was last updated on 2/17/2025 by MarketBeat.com Staff
